Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1943 1
1946 3
1947 1
1948 3
1949 2
1950 3
1951 2
1952 5
1953 4
1954 1
1955 9
1956 7
1957 8
1958 18
1959 14
1960 9
1961 4
1962 3
1963 12
1964 15
1965 9
1966 15
1967 12
1968 22
1969 17
1970 27
1971 9
1972 18
1973 17
1974 14
1975 14
1976 23
1977 21
1978 17
1979 32
1980 29
1981 40
1982 29
1983 38
1984 21
1985 33
1986 31
1987 38
1988 44
1989 40
1990 39
1991 48
1992 39
1993 47
1994 45
1995 46
1996 64
1997 52
1998 59
1999 58
2000 71
2001 70
2002 74
2003 87
2004 91
2005 110
2006 127
2007 111
2008 149
2009 139
2010 152
2011 165
2012 172
2013 190
2014 199
2015 185
2016 224
2017 209
2018 192
2019 174
2020 176
2021 202
2022 214
2023 168
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

4,523 results

Results by year

Filters applied: . Clear all
Page 1
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.
Kramer MH, Zhang Q, Sprung R, Day RB, Erdmann-Gilmore P, Li Y, Xu Z, Helton NM, George DR, Mi Y, Westervelt P, Payton JE, Ramakrishnan SM, Miller CA, Link DC, DiPersio JF, Walter MJ, Townsend RR, Ley TJ. Kramer MH, et al. Blood. 2022 Sep 29;140(13):1533-1548. doi: 10.1182/blood.2022016033. Blood. 2022. PMID: 35895896 Free PMC article.
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M. Bornhäuser M, et al. Among authors: kramer m. JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605. JAMA Oncol. 2023. PMID: 36757706 Free PMC article. Clinical Trial.
Therapie des Prostatakarzinoms.
Kramer MW. Kramer MW. Aktuelle Urol. 2022 Feb;53(1):29-30. doi: 10.1055/a-1658-3563. Epub 2022 Jan 25. Aktuelle Urol. 2022. PMID: 35078251 German. No abstract available.
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.
Javitt A, Shmueli MD, Kramer MP, Kolodziejczyk AA, Cohen IJ, Radomir L, Sheban D, Kamer I, Litchfield K, Bab-Dinitz E, Zadok O, Neiens V, Ulman A, Wolf-Levy H, Eisenberg-Lerner A, Kacen A, Alon M, Rêgo AT, Stacher-Priehse E, Lindner M, Koch I, Bar J, Swanton C, Samuels Y, Levin Y, da Fonseca PCA, Elinav E, Friedman N, Meiners S, Merbl Y. Javitt A, et al. Among authors: kramer mp. Nat Cancer. 2023 May;4(5):629-647. doi: 10.1038/s43018-023-00557-4. Epub 2023 May 22. Nat Cancer. 2023. PMID: 37217651
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Taube F, et al. Among authors: kramer m. Blood. 2022 Jan 6;139(1):87-103. doi: 10.1182/blood.2020009680. Blood. 2022. PMID: 34320176 Free article.
Susac Syndrome.
Krämer M, Dörr J, Ringelstein M, Krämer B, Groß CC, Kleffner I. Krämer M, et al. Dtsch Arztebl Int. 2022 Apr 1;119(13):230. doi: 10.3238/arztebl.m2022.0059. Dtsch Arztebl Int. 2022. PMID: 35773987 Free PMC article. No abstract available.
Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.
Kacen A, Javitt A, Kramer MP, Morgenstern D, Tsaban T, Shmueli MD, Teo GC, da Veiga Leprevost F, Barnea E, Yu F, Admon A, Eisenbach L, Samuels Y, Schueler-Furman O, Levin Y, Nesvizhskii AI, Merbl Y. Kacen A, et al. Among authors: kramer mp. Nat Biotechnol. 2023 Feb;41(2):239-251. doi: 10.1038/s41587-022-01464-2. Epub 2022 Oct 6. Nat Biotechnol. 2023. PMID: 36203013
Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics.
Bhatia S, Kramer M, Russo S, Naik P, Arun G, Brophy K, Andrews P, Fan C, Perou CM, Preall J, Ha T, Plenker D, Tuveson DA, Rishi A, Wilkinson JE, McCombie WR, Kostroff K, Spector DL. Bhatia S, et al. Among authors: kramer m. Cancer Res. 2022 Apr 1;82(7):1174-1192. doi: 10.1158/0008-5472.CAN-21-2807. Cancer Res. 2022. PMID: 35180770 Free PMC article.
Landelijke diabetesregistratie DPARD: vijf jaar succesvol op weg.
Verheugt CL, de Vries SAG, Bak JCG, Serné EH, Kramer MHH. Verheugt CL, et al. Among authors: kramer mhh. Ned Tijdschr Diabetol. 2023;21(1):13-15. doi: 10.1007/s12467-023-1212-9. Epub 2023 Mar 8. Ned Tijdschr Diabetol. 2023. PMID: 36909670 Free PMC article. Dutch. No abstract available.
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, Blazar BR, Radojcic V, Zeidner JF, Arruda A, Wang B, Abbas HA, Minden MD, Tasian SK, Bornhäuser M, Gojo I, Luznik L. Rutella S, et al. Among authors: kramer m. J Clin Invest. 2022 Nov 1;132(21):e159579. doi: 10.1172/JCI159579. J Clin Invest. 2022. PMID: 36099049 Free PMC article.
4,523 results